Enovis Corporation (ENOV)
Enovis Corporation (ENOV) is a global medical device company specializing in orthopedics, regenerative medicine, and surgical solutions. It provides innovative products designed to improve patient outcomes and enhance healthcare. The company focuses on delivering surgical instruments, implants, and regenerative therapies across various medical specialties.
Company News
Enovis Corporation will participate in three investor conferences in August and September 2025, including Canaccord Genuity, Wells Fargo Healthcare, and Baird Global Healthcare Conferences.
Medical technology company Enovis reported Q2 2025 revenue of $564.5 million, up 7% year-over-year, beating analyst estimates. The company raised full-year guidance and saw strong performance in its Reconstructive segment, despite ongoing integration and regulatory challenges.
Enovis has introduced the AltiVate Reverse Glenoid System, a new solution for reverse shoulder arthroplasty. The system offers modular and augmented baseplates, providing surgeons with more options to improve implant longevity and optimize patient outcomes.
In the latest quarter, 6 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bea...